Findings

What do systematic reviews say?

22 questions · 22 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 36.4%GRADE not reported 0 · 0%Very low 8 · 36.4%Low 5 · 22.7%Moderate 1 · 4.5%High 0 · 0%

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Time to response ‐ not measured · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

Quality of life ‐ not measured · stage III cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found